Skip to main content

Alaunos Therapeutics, Inc.

TCRT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001107421

No open-market purchases or sales by Alaunos Therapeutics, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $204.4K in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Alaunos Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Alaunos Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Alaunos Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Weis HolgerCEO25,483Aug 11, 20265
Jerman Michael AllenDirector23,759Jul 27, 20264
Postma Robert WDirector58,609Jul 27, 20264
Vieser JaimeDirector47,642Jul 27, 20264
Groenewald FerdinandVice President of Finance10,775Aug 20, 20250
Lackey MelindaLegal & Administration–Apr 1, 20250
Hogue Dale Curtis Jr.See Remarks–Apr 1, 20250
Hofmeister RobertDirector–Jun 10, 20240
Boyle Kevin S. Sr.Chief Executive Officer798,236Sep 5, 20230
Thistle MaryDirector45,000Jun 8, 20230
Huang JamesDirector188,333Jun 8, 20230
Wong MichaelVice President, Finance–Mar 17, 20230
Deniger DrewSee Remarks–Mar 17, 20230
Srivastava Abhishek KSee Remarks–Mar 17, 20230
Bowden ChristopherDirector44,167Jun 24, 20220
De Groot EleanorEVP, Operations237,106Apr 1, 20220
Hagen HeidiDirector145,889Sep 3, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jun 26, 2025 (view filing)Jun 242 daysVieser JaimeDirectorPPurchase+55.7K$0.0202+$1.12K–250 afterDerivative
Jun 26, 2025 (view filing)Apr 11-Jun 2476 daysLatePostma Robert WDirectorPPurchase+314.8K$0.0129+$4.07K–600 afterDerivative2 lots
Apr 15, 2025 (view filing)Apr 114 daysPostma Robert WDirectorPPurchase+181.2K$0.0076+$1.38K–500 afterDerivative
Jan 3, 2025 (view filing)Dec 31, 20243 daysVieser JaimeDirectorSSale−3.00K$2.01−$6.02K−10.4%25.9K after2 lots
Sep 5, 2023 (view filing)5:34 PM ETSep 14 daysBoyle Kevin S. Sr.Chief Executive OfficerSSale−68.0K$0.1403−$9.54K−7.9%798.2K after10b5-1
Dec 1, 2022 (view filing)Nov 292 daysPostma Robert WDirectorPPurchase+750.0K$0.65+$487.5K+17.6%5.00M after
Dec 1, 2022 (view filing)Nov 292 daysVieser JaimeDirectorPPurchase+1.25M$0.65+$812.5KNew position1.25M after
Dec 27, 2021 (view filing)Dec 225 daysDe Groot EleanorEVP, OperationsSSale−20.1K$1.27−$25.6K−7.8%237.1K after
Nov 17, 2021 (view filing)Nov 16-171 dayBoyle Kevin S. Sr.Chief Executive OfficerPPurchase+10.0K$1.40+$14.0K+1.1%885.0K after2 lots
Oct 4, 2021 (view filing)Sep 295 daysLateVieser JaimeDirectorPPurchase+100.0K$1.91+$191.0K+16.5%705.3K after
Sep 3, 2021 (view filing)Sep 21 dayHagen HeidiDirectorPPurchase+23.8K$1.76+$41.8K+19.5%145.9K after
Sep 3, 2021 (view filing)Sep 12 daysWeis HolgerDirectorPPurchase+50.0K$1.83+$91.5K+71.3%120.2K after
Sep 3, 2021 (view filing)Sep 21 dayPostma Robert WDirectorPPurchase+20.5K$1.73+$35.5K+1.7%1.20M after
Sep 3, 2021 (view filing)Sep 21 dayPostma Robert WDirectorPPurchase+54.5K$1.73+$94.3K+1.3%4.25M after
Sep 3, 2021 (view filing)Sep 12 daysHuang JamesDirectorPPurchase+100.0K$1.71+$171.0K+1,200.0%108.3K after